According to the agreement, Sanofi will invest $80 million in newly issued JHL shares and will pay $21 million upfront for exclusive rights to the proposed biosimilar and options to certain other JHL Biotech products currently under development.
JHL Biotech will lead the development, registration and manufacturing of the biosimilar, while Sanofi will direct commercialization efforts in China.
“Today is a turning point in JHL’s history,” said Racho Jordanov, cofounder and CEO of JHL Biotech. “JHL was built on the foundation of world-class biologics capabilities. In our alliance with Sanofi, we are combining JHL’s development and manufacturing expertise with Sanofi’s strengths in commercialization. Together, we will make high-quality medicines affordable to more patients in China.”
“The alliance reflects Sanofi’s long-term commitment to invest in China and to provide access to high-quality therapeutics to Chinese patients,” said Jean-Luc Lowinski, MD, president of Sanofi China and senior vice president of Sanofi Asia. “JHL has quickly developed leading capabilities in the development of biologics and I am confident that our alliance will positively impact the lives of patients in areas of high unmet medical needs in China.”
More articles on supply chain:
Sodexo Healthcare to partner with Alliance HealthCare Radiology
Medtronic, Fitbit join forces on mobile app to help individuals with diabetes
Trump’s potential FDA chief has supported letting patients use drugs ‘at their own risk’: 7 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
